Effect of Spironolactone on Cardiovascular Complications Associated with Type-2 Diabetes in Rats

Abstract

We have studied the effect spironolactone (20 mg/kg/day) on cardiovascular complications in neonatal model of diabetes in rats, induced by administering 90 mg/kg streptozotocin (STZ), i.p. in 2 day old rats. Diabetes was checked after 12 weeks. At the end of 8 weeks of treatment, various biochemical and cardiac parameters were measured. STZ produced hyperglycemia, hyperinsulinemia, dyslipidemia, increased creatinine, cardiac enzyme and C-reactive protein (CRP) levels, worsened hemodynamic parameters, cardiac hypertrophy and oxidative stress. Chronic treatment with spironolactone significantly reduced serum glucose levels but did not alter insulin levels. It also significantly prevented the dyslipidemia and reduced elevated Lactate de-hydrogenase, creatinine kinase, CRP and creatinine levels. Chronic treatment with spironolactone prevented STZ-induced hypertension, tachycardia and elevated rate of pressure development and decay. Spironolactone also produced beneficial effect by preventing cardiac hypertrophy as evident from left ventricular collagen levels, cardiac and left ventricular hypertrophic indices and prevented oxidative stress. In conclusion, our data suggests that spironolactone prevents STZ induced metabolic abnormalities and cardiovascular complications in animal model of type 2 diabetes.

Combination of Telmisartan with Cisplatin Controls Oral Cancer Cachexia in Rats

“…The left ventricular dysfunction has been associated with a decrease in rate of pressure of pressure development and decay [32, 33]. In the present study, combination of telmisartan with cisplatin improved the hemodynamic functions while cisplatin alone did not.…”

The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin‐induced diabetes

“…Infusion of aldosterone in rats similarly increased vascular NADPH oxidase and plasma TBARS (a markers of lipid peroxidation), and treatment with spironolactone reduced these effects . In a neonatal model of STZ‐induced DM, spironolactone reduced oxidative stress and cardiac hypertrophy and improved glucose and lipid profiles, suggesting that it could be used to prevent cardiac and metabolic complications of DM …”

“…The compensatory elevation in myocardial activities of catalase, SOD, and GSH peroxidases/reductases likely also prevented changes in either lipid peroxidation levels (TBARS) or the GSH/GSSG ratio between our study groups. Increased levels of SOD, GPx, and catalase were reported in some studies of STZ‐diabetic rats, while decreased in others . Discrepancies between findings might be related to the differences in the rat strain, gender, and age, as well as the dose, duration, and administration route of STZ that affect DM severity …”

Cohort Profile: Sympathetic activity and Ambulatory Blood Pressure in Africans (SABPA) prospective cohort study

“…We addressed this crucial matter and an ethnic-specific waist circumference (WC) cut-point model for Africans was proposed. 19 , 30 The model was validated by utilizing diagnostic tests and non-linear analyses. 19 Furthermore, supporting the brain-heart link, we revealed that the validated ethnic-specific WC cut-point model (African men, ≥90 cm; -women, ≥98 cm) was associated with cognitive emotional distress and sub-clinical atherosclerosis.…”